US 7517886
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
granted A61KA61K31/506A61K31/519
Quick answer
US patent 7517886 (Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds) held by Rigel Pharmaceuticals, Inc. expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 28
- CPC classes
- A61K, A61K31/506, A61K31/519, A61P, A61P1/00